Pharvaris N.V. (NASDAQ:PHVS) Receives $34.00 Average PT from Analysts

Key Points

• Pharvaris N.V. (NASDAQ:PHVS) has an average consensus recommendation of "Moderate Buy" from five brokerage firms, with four having issued buy ratings.
• The stock currently has an average 1-year target price of $34.00, despite notable variability in price targets from different analysts.
• Pharvaris reported a loss of ($0.94) EPS for the most recent quarter, missing the consensus estimate by $0.07 and is forecasted to post -$2.71 EPS for the current fiscal year.

Shares of Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) have received an average rating of "Moderate Buy" from the five research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $34.00.

Several brokerages recently issued reports on PHVS. JMP Securities dropped their price objective on shares of Pharvaris from $55.00 to $52.00 and set a "market outperform" rating for the company in a research note on Wednesday, August 13th. Guggenheim began coverage on shares of Pharvaris in a research note on Wednesday, June 11th. They set a "buy" rating and a $32.00 price objective for the company. Zacks Research raised shares of Pharvaris from a "strong sell" rating to a "hold" rating in a research note on Monday, August 18th. Finally, Wedbush reaffirmed an "outperform" rating and set a $27.00 price objective on shares of Pharvaris in a research note on Thursday, June 5th.

Institutional Trading of Pharvaris

Several hedge funds have recently made changes to their positions in PHVS. Northern Trust Corp grew its stake in shares of Pharvaris by 483.9% in the 4th quarter. Northern Trust Corp now owns 91,932 shares of the company's stock valued at $1,762,000 after buying an additional 76,188 shares during the period. Bank of America Corp DE boosted its position in shares of Pharvaris by 205,286.7% during the 4th quarter. Bank of America Corp DE now owns 30,808 shares of the company's stock worth $591,000 after purchasing an additional 30,793 shares during the period. Deutsche Bank AG boosted its position in shares of Pharvaris by 13.0% during the 4th quarter. Deutsche Bank AG now owns 18,168 shares of the company's stock worth $348,000 after purchasing an additional 2,087 shares during the period. Point72 Asset Management L.P. purchased a new position in shares of Pharvaris during the 4th quarter worth approximately $152,000. Finally, Woodline Partners LP purchased a new position in shares of Pharvaris during the 4th quarter worth approximately $853,000.

Pharvaris Stock Performance

Shares of PHVS traded down $0.37 during mid-day trading on Friday, hitting $24.99. 314,197 shares of the company were exchanged, compared to its average volume of 157,372. Pharvaris has a 1-year low of $11.51 and a 1-year high of $26.33. The company has a 50 day moving average of $22.34 and a 200-day moving average of $18.43. The stock has a market cap of $1.31 billion, a price-to-earnings ratio of -7.44 and a beta of -2.80.

Pharvaris (NASDAQ:PHVS - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.07). Research analysts anticipate that Pharvaris will post -2.71 earnings per share for the current fiscal year.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.